Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Share-based Compensation (2016 - 2025)

Bio-Techne has reported Share-based Compensation over the past 17 years, most recently at $500000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $500000.0 for Q4 2025, up 25.0% from a year ago — trailing twelve months through Dec 2025 was $28.4 million (up 10.15% YoY), and the annual figure for FY2025 was $40.8 million, up 7.34%.
  • Share-based Compensation for Q4 2025 was $500000.0 at Bio-Techne, down from $11.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TECH hit a ceiling of $14.5 million in Q3 2022 and a floor of -$2.1 million in Q2 2023.
  • Median Share-based Compensation over the past 5 years was $9.6 million (2022), compared with a mean of $7.7 million.
  • Peak annual rise in Share-based Compensation hit 4219.33% in 2023, while the deepest fall reached 124.8% in 2023.
  • Bio-Techne's Share-based Compensation stood at $300000.0 in 2021, then changed by 0.0% to $300000.0 in 2022, then surged by 4219.33% to $13.0 million in 2023, then plummeted by 96.91% to $400000.0 in 2024, then increased by 25.0% to $500000.0 in 2025.
  • The last three reported values for Share-based Compensation were $500000.0 (Q4 2025), $11.7 million (Q3 2025), and $4.6 million (Q2 2025) per Business Quant data.